Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - SELLAS Life Sciences Group, Inc. | b85268e8vk.htm |
| EX-5.1 - EX-5.1 - SELLAS Life Sciences Group, Inc. | b85268exv5w1.htm |
| EX-1.1 - EX-1.1 - SELLAS Life Sciences Group, Inc. | b85268exv1w1.htm |
| EX-4.2 - EX-4.2 - SELLAS Life Sciences Group, Inc. | b85268exv4w2.htm |
| EX-4.1 - EX-4.1 - SELLAS Life Sciences Group, Inc. | b85268exv4w1.htm |
| EX-99.2 - EX-99.2 - SELLAS Life Sciences Group, Inc. | b85268exv99w2.htm |
Exhibit 99.1
RXi Pharmaceuticals Announces Public Offering of Common Stock and Warrants
WORCESTER, Mass., February 28, 2011 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (Nasdaq:
RXII) today announced that it is offering to sell shares of its common stock and common stock
purchase warrants in an underwritten public offering. All of the securities in the offering are to
be sold by RXi. The offering is subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual size or terms of the offering.
Lazard Capital Markets LLC is acting as the sole book-running manager for the offering and ROTH
Capital Partners, LLC is acting as co-manager.
The securities described above are being offered by RXi Pharmaceuticals pursuant to a shelf
registration statement on Form S-3, together with a base prospectus, previously filed and declared
effective by the Securities and Exchange Commission (SEC). The securities may be offered only by
means of a prospectus. A preliminary prospectus supplement relating to and describing the terms of
the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov.
When available, copies of the preliminary prospectus supplement and the final prospectus
supplement may be also obtained from Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor,
New York, NY 10020 or via telephone at (800) 542-0970 or from ROTH Capital Partners, LLC,
Attention: Prospectus Department, 24 Corporate Plaza Drive, Newport Beach, CA 92660 or via
telephone at (800) 678-9147.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any
securities of RXi Pharmaceuticals Corporation, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or jurisdiction.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a recognized leader in RNAi-based therapeutics with a comprehensive platform
that includes both RNA interference (RNAi) compounds and delivery technologies. The company is
leveraging this broad and integrated platform to build a pipeline of RNAi therapeutic candidates
for the treatment of a number of disease areas, including its core focus of developing treatments
for dermal anti-scarring and retinal disorders as well as a continued interest in oncology and
indications accessible by spinal cord delivery. RXi Pharmaceuticals believes it is well positioned
to compete successfully in the RNAi therapeutics market based on the strength of its next
generation RNAi platform, experienced management team, accomplished Scientific Advisory Board,
including Nobel Laureate, Dr. Craig Mello, and its broad intellectual property position in RNAi
chemistry and delivery. http://www.rxipharma.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about
the offering. These forward-looking statements involve significant risks,
uncertainties and assumptions, including the risk that the offering does not close. RXi
Pharmaceuticals Corporation does not undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur after the date of this release.
SOURCE: RXi Pharmaceuticals Corporation
RXi Pharmaceuticals
Donna Falcetti, 508-929-3615
ir@rxipharma.com
or
Investors
S. A. Noonan Communications
Susan Noonan, 212-966-3650
susan@sanoonan.com
or
Media
Rx Communications Group
Eric Goldman, 917-322-2563
egoldman@rxir.com
Donna Falcetti, 508-929-3615
ir@rxipharma.com
or
Investors
S. A. Noonan Communications
Susan Noonan, 212-966-3650
susan@sanoonan.com
or
Media
Rx Communications Group
Eric Goldman, 917-322-2563
egoldman@rxir.com